Related Experiment Video
Updated: May 16, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Antidiabetic effect of compounds isolated from plants
R M Perez G1, M A Zavala S, S Perez G
1Laboratorio de Investigacion de Productos Naturales. Escuela Superior de Ingenieria Quimica e Industrias Extractivas IPN. Punto Fijo 16 Col. Torres Lindavista CP 07050. Mexico D.F.
Summary
This review explores plant compounds with hypoglycemic effects, detailing their chemical groups, pharmacological actions, and mechanisms. It covers diverse substances like flavonoids, alkaloids, and mucilages, aiding in diabetes research.
Area of Science:
- Pharmacology and Phytochemistry
- Natural Product Chemistry
Background:
- Plants have historically been a source of therapeutic agents.
- A demonstrated hypoglycemic effect in plants suggests the presence of bioactive compounds.
- Understanding these compounds is crucial for developing new anti-diabetic treatments.
Purpose of the Study:
- To review and classify chemical compounds isolated from plants with known hypoglycemic activity.
- To summarize the pharmacological properties, mechanisms of action, and other relevant data for these compounds.
- To provide a comprehensive overview of hypoglycemic substances found in medicinal plants.
Main Methods:
- Literature review of scientific publications.
- Identification and classification of compounds based on chemical structure.
- Compilation of data on pharmacological activity and mechanisms of action.
Main Results:
- Compounds reviewed include mucilages, glycans, proteins, pectins, flavonoids, steroids, triterpenoids, alkaloids, and other nitrogenous substances.
- Detailed information on the hypoglycemic effects, pharmacological actions, and mechanisms of these diverse compounds is presented.
- The classification aids in understanding structure-activity relationships.
Conclusions:
- Various chemical classes of plant-derived compounds exhibit significant hypoglycemic activity.
- Further research into these compounds can lead to novel therapeutic strategies for managing hyperglycemia and diabetes.
- This review serves as a valuable resource for researchers in pharmacognosy and medicinal chemistry.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...